Ard J. Van Veelen

Utrecht, UT, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer.

Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer.

Journal: International journal of cancer

Published: December 29, 2022

Development and validation of an HPLC-MS/MS method to simultaneously quantify brigatinib, lorlatinib, pralsetinib and selpercatinib in human K2-EDTA plasma.

Development and validation of an HPLC-MS/MS method to simultaneously quantify brigatinib, lorlatinib, pralsetinib and selpercatinib in human K2-EDTA plasma.

Journal: Biomedical chromatography : BMC

Published: November 28, 2022

Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib.

Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib.

Journal: JTO clinical and research reports

Published: September 22, 2022

Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial.

Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: April 20, 2022

Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors.

Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors.

Journal: Cancer epidemiology

Published: June 25, 2021

Development and validation of an HPLC-MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run.

Development and validation of an HPLC-MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples, using one assay run.

Journal: Biomedical chromatography : BMC

Published: January 08, 2021

Validation of an analytical method using HPLC-MS/MS to quantify osimertinib in human plasma and supplementary stability results.

Validation of an analytical method using HPLC-MS/MS to quantify osimertinib in human plasma and supplementary stability results.

Journal: Biomedical chromatography : BMC

Published: July 08, 2019

Impact of Average Daily and Cumulative Dose of Statins on Mortality Risk Among Healthy Elderly.

Impact of Average Daily and Cumulative Dose of Statins on Mortality Risk Among Healthy Elderly.

Journal: The American journal of medicine

Published: February 18, 2019

Comment on "Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark".

Comment on "Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark".

Journal: Journal of the American Academy of Dermatology

Published: January 11, 2019

Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies.

Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies.

Journal: PharmacoEconomics

Published: December 08, 2017

Showing 1-10 of 10

Last Updated: 09/26/2026